Prof. PeptideProf. Peptide

BPC-157 vs TB-500 — Recovery Peptide Comparison

BPC-157 and TB-500 are both studied for tissue repair and are frequently stacked together. No head-to-head human trial of the two exists. This page reports what each compound is, which studies apply to which compound, and the evidence level for each — without conflating TB-500 with the separate protein Thymosin Beta-4.

On this page
  1. 1.Molecule Identity
  2. 2.Human Evidence, by Molecule
  3. 3.Animal Evidence
  4. 4.Evidence Level
  5. 5.FAQ
  6. 6.References

Molecule Identity

BPC-157 is a synthetic 15-amino-acid peptide based on a protective protein found in human gastric juice. TB-500 is not a standalone discovery — Esposito et al. 2012 (Drug Test Anal, PMID 22962027), an anti-doping laboratory's mass-spectrometry analysis of a commercial TB-500 product, identified it as the N-terminal acetylated 17-23 fragment of Thymosin Beta-4 (Ac-LKKTETQ), 7 amino acids — not the 43-amino-acid full-length Thymosin Beta-4 protein. Material and studies referring to native, full-length Thymosin Beta-4 (including the RegeneRx human trials and the Bock-Marquette cardiac paper) are not evidence for the TB-500 fragment; see the dedicated TB-500 vs Thymosin Beta-4 page for that distinction.

BPC-157TB-500
What it is15-amino-acid synthetic peptide, derived from a protein in human gastric juiceSynthetic 7-amino-acid N-terminal acetylated fragment of Thymosin Beta-4 (Ac-LKKTETQ), per mass-spec identification (Esposito et al. 2012, PMID 22962027)
Proposed mechanismAngiogenesis (VEGF/eNOS upregulation), EGR-1-mediated growth factor signaling, FAK-paxillin pathway in tendonActin sequestration and cell migration, angiogenesis, macrophage polarization (M1→M2)
Human evidenceLee & Padgett 2021 (PMID 34324435) — retrospective case series, intra-articular knee injectionNone identified for the TB-500 fragment itself
Animal evidenceBiçer et al. 2026 (PMID 42542926) — rat Achilles-tendon-transection model; multiple other rodent studies cited on the BPC-157 profileBiçer et al. 2026 (PMID 42542926) — same rat Achilles-tendon-transection model, dosed as “synthetic thymosin beta-4 (TB-500)”
Evidence levelHuman ObservationalAnimal Model
FDA statusNot FDA-approved; FDA lists it as nominated but withdrawn (previously Category 2), not in Category 1Not FDA-approved; FDA lists it as nominated but withdrawn (previously Category 2), not in Category 1

Figures in the rows above come from different studies, different species (rat vs human), and different routes of administration (intraperitoneal, intra-articular). No entry here should be read as directly comparable to another row without checking the source study.

Human Evidence, by Molecule

BPC-157's human evidence is Lee & Padgett 2021 (Altern Ther Health Med, PMID 34324435), a retrospective chart review of 17 patients (16 reached for follow-up) who received an intra-articular knee injection of BPC-157 at 4 mg, most receiving a single injection. This is a retrospective, uncontrolled case series — Human Observational evidence, not a randomized trial — and the dose and route (intra-articular, into the knee joint) are specific to that study; it does not establish evidence for the subcutaneous or systemic route more commonly used in research protocols.

No human trial of TB-500 itself has been identified. Two RegeneRx-sponsored Phase 2 trials (NCT00382174, pressure ulcers; NCT00311766, epidermolysis bullosa) tested native, full-length Thymosin Beta-4, not the TB-500 fragment, and are not counted as TB-500 evidence.

Animal Evidence

Biçer et al. 2026 (Jt Dis Relat Surg, PMID 42542926) is a rat Achilles-tendon-transection model (N=32, four arms of 8) testing BPC-157 alone (10 µg/kg/day intraperitoneally), TB-500 alone (dosed in the paper's own methods as “synthetic thymosin beta-4 (TB-500)” at 60 µg/kg/day intraperitoneally), and the combination, over four weeks. This is the one study located that administers and names both compounds in the same experiment.

TB-500 alone produced a significantly higher maximum load to failure than controls and significantly lower (improved) total Bonar and Movin histopathology scores. The BPC-157-alone group showed a higher maximum load to failure than controls, but its histopathological scores did not reach statistical significance for the total score. The combination did not confer additional benefit over TB-500 alone in this study.

Adverse events reported in the same study

Biçer et al. 2026 reported no animal deaths, postoperative infections, wound complications, tendon reruptures, or protocol-related exclusions in any of the four treatment groups over the 4-week study. Lee & Padgett 2021 reported no serious adverse events in its 17-patient chart review of intra-articular BPC-157.

Evidence Level

BPC-157: Human Observational (Lee & Padgett 2021, PMID 34324435 — intra-articular knee injection, not the subcutaneous route commonly used in research protocols). TB-500: Animal Model (Biçer et al. 2026, PMID 42542926). Full profiles, including each compound's wider citation list, are on the BPC-157 and TB-500 profile pages.

FAQ

Are BPC-157 and TB-500 the same kind of evidence?

No. BPC-157's strongest cited evidence includes a human study — Lee & Padgett 2021 (PMID 34324435), a retrospective case series of 17 patients who received an intra-articular (into the knee joint) injection of BPC-157. TB-500's evidence located for this page is Animal Model only: Biçer et al. 2026 (PMID 42542926), a rat Achilles-tendon study. Neither figure generalizes to the other route or species.

Is the Nature paper on cardiac cell migration evidence for TB-500?

No. That paper (Bock-Marquette et al. 2004, PMID 15565145) administered native, full-length Thymosin Beta-4 — a 43-amino-acid protein — not the 7-amino-acid TB-500 fragment identified by Esposito et al. 2012 (PMID 22962027). See the TB-500 vs Thymosin Beta-4 page for the full molecule-identity breakdown.

Is there a study that tested BPC-157 and TB-500 together?

Yes — Biçer et al. 2026 (PMID 42542926) is a rat Achilles-tendon-transection model with four arms: control, BPC-157 alone, TB-500 alone, and the combination. TB-500 alone produced the strongest biomechanical result of the three treatment arms; the combination did not confer additional benefit over TB-500 alone in that study. This is the only study located that directly compares the two compounds in the same experiment, and it is an animal, not a human, study.

Does the intra-articular BPC-157 study apply to the subcutaneous route research commonly uses?

Not directly. Lee & Padgett 2021 injected BPC-157 into the knee joint (intra-articular), not subcutaneously. It is a retrospective, uncontrolled case series, not a randomized trial, and its dose and route are specific to that study.

References

  1. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/
  2. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://pubmed.ncbi.nlm.nih.gov/42542926/
  3. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
  4. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
BPC-157 ProfileTB-500 ProfileBPC-157 Dosing GuideTB-500 Dosing GuideTB-500 vs Thymosin Beta-4

Have a question about BPC-157 vs TB-500 — Evidence, Mechanism, and Molecule Identity? Send us an email